JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality-Reference-Cited by-同舟云学术

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Published:2021-01 Issue:1 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Stebbing Justin¹^ORCID,Sánchez Nievas Ginés²^ORCID,Falcone Marco³,Youhanna Sonia⁴^ORCID,Richardson Peter⁵,Ottaviani Silvia¹^ORCID,Shen Joanne X.⁴,Sommerauer Christian⁶^ORCID,Tiseo Giusy³,Ghiadoni Lorenzo³,Virdis Agostino³,Monzani Fabio³^ORCID,Rizos Luis Romero⁷⁸,Forfori Francesco⁹^ORCID,Avendaño Céspedes Almudena⁷⁸,De Marco Salvatore¹⁰^ORCID,Carrozzi Laura⁹,Lena Fabio¹¹^ORCID,Sánchez-Jurado Pedro Manuel⁷⁸,Lacerenza Leonardo Gianluca¹¹^ORCID,Cesira Nencioni¹²^ORCID,Caldevilla Bernardo David¹³^ORCID,Perrella Antonio¹²,Niccoli Laura¹⁴,Méndez Lourdes Sáez¹⁵,Matarrese Daniela¹⁶^ORCID,Goletti Delia¹⁷^ORCID,Tan Yee-Joo¹⁸^ORCID,Monteil Vanessa¹⁹^ORCID,Dranitsaris George²⁰,Cantini Fabrizio¹⁴,Farcomeni Alessio²¹^ORCID,Dutta Shuchismita²²^ORCID,Burley Stephen K.²²,Zhang Haibo²³^ORCID,Pistello Mauro²⁴^ORCID,Li William²⁵^ORCID,Romero Marta Mas⁷,Andrés Pretel Fernando²⁶,Simón-Talero Rafaela Sánchez²⁷,García-Molina Rafael⁷^ORCID,Kutter Claudia⁶^ORCID,Felce James H.²⁸^ORCID,Nizami Zehra F.²⁸^ORCID,Miklosi Andras G.²⁸,Penninger Josef M.²⁹³⁰^ORCID,Menichetti Francesco³,Mirazimi Ali¹⁸,Abizanda Pedro⁷⁸^ORCID,Lauschke Volker M.⁴^ORCID

Affiliation:

1. Department of Surgery and Cancer, Imperial College, London, UK.

2. Department of Rheumatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

3. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

4. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

5. BenevolentAI, Maple Street, London, UK.

6. Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Science for Life Laboratory, Solna, Sweden.

7. Department of Geriatric Medicine, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

8. CIBERFES, Ministerio de Economía y Competitividad, Madrid, Spain.

9. Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, Pisa, University of Pisa, Italy.

10. Department of Internal Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

11. Department of Pharmaceutical Medicine, Misericordia Hospital, Grosseto, Italy.

12. Department of Medicine, Misericordia Hospital, Grosseto, Italy.

13. Department of Radiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

14. Department of Rheumatology, Hospital of Prato, Prato, Italy.

15. Department of Internal Medicine, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

16. Hospital Network ASL Toscana Centro, Toscana, Italy.

17. Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases–IRCCS, Rome, Italy.

18. University of Singapore, Infectious Diseases Programme, Immunology Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore and Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore, Singapore.

19. Karolinska Institutet, Department of Laboratory Medicine, Unit of Clinical Microbiology, and SE-17177, Stockholm, Sweden.

20. Department of Hematology, School of Medicine, University of Ioannina, Ioannina, Greece.

21. Department of Economics and Finance, University of Rome Tor Vergata, Rome Italy.

22. RCSB Protein Data Bank, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.

23. Departments of Anesthesia, Medicine, and Physiology, University of Toronto, Toronto, ON, Canada.

24. Virology Unit, Department of Translational Research, University of Pisa, Pisa, Italy.

25. The Angiogenesis Foundation, Cambridge, MA, USA.

26. Department of Statistics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

27. Department of Pneumology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

28. Oxford Nanoimaging, Oxford, UK.

29. Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.

30. Department of Medical Genetics, Life Science Institute, University of British Columbia, Vancouver, BC, Canada.

Abstract

The dual anticytokine and antiviral actions of baricitinib reduce SARS-CoV-2 infectivity in organoids and morbidity in people.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference55 articles.

1. Covid-19 — Navigating the Uncharted

2. Coronavirus Infections—More Than Just the Common Cold

3. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

4. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

5. Covid-19 — The Search for Effective Therapy

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sclareol exerts an anti-inflammatory effect, possibly through COXs inhibition pathway: In vivo and in silico studies;Pharmaceutical Science Advances;2024-12

2. Discovery of a novel inhibitor of macropinocytosis with antiviral activity;Molecular Therapy;2024-09

3. The Interplay between Airway Cilia and Coronavirus Infection, Implications for Prevention and Control of Airway Viral Infections;Cells;2024-08-14

4. The AI Future of Emergency Medicine;Annals of Emergency Medicine;2024-08

5. Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies;International Journal of Molecular Sciences;2024-07-26